GARDASIL® [Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine, Recombinant], Merck’s HPV Vaccine, Available to Developing Countries through UNICEF Tender

Dateline City:  WHITEHOUSE STATION, N.J. WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today that the company has been awarded a significant portion of the UNICEF human papillomavirus (HPV) vaccine tender, and will provide sustained supply of GARDASIL® [Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine, Recombinant] to GAVI-eligible countries. This agreement follows the GAVI Alliance’s earlier announcement that HPV vaccines would be included in its portfolio for the first time. Language:  English Contact HTML:  MerckMedia:Pamela Eisele, 908-423-5042orImraan Munshi, 215-652-0059orInvestors:Carol Ferguson, 908-423-4465orJustin Holko, 908-423-5088 Ticker Slug:  Ticker: MRK Exchange: NYSE read more
Source: Merck.com - Corporate News - Category: Pharmaceuticals Authors: Tags: Prescription Medicine News Vaccine News Corporate News Latest News Source Type: news